KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Total Liabilities: 2011-2025

Historic Total Liabilities for Supernus Pharmaceuticals (SUPN) over the last 14 years, with Sep 2025 value amounting to $370.1 million.

  • Supernus Pharmaceuticals' Total Liabilities rose 10.29% to $370.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $370.1 million, marking a year-over-year increase of 10.29%. This contributed to the annual value of $332.3 million for FY2024, which is 6.69% down from last year.
  • Per Supernus Pharmaceuticals' latest filing, its Total Liabilities stood at $370.1 million for Q3 2025, which was up 16.20% from $318.5 million recorded in Q2 2025.
  • In the past 5 years, Supernus Pharmaceuticals' Total Liabilities ranged from a high of $879.7 million in Q1 2023 and a low of $316.6 million during Q1 2025.
  • In the last 3 years, Supernus Pharmaceuticals' Total Liabilities had a median value of $358.4 million in 2024 and averaged $398.9 million.
  • Its Total Liabilities has fluctuated over the past 5 years, first skyrocketed by 30.62% in 2021, then crashed by 57.38% in 2024.
  • Over the past 5 years, Supernus Pharmaceuticals' Total Liabilities (Quarterly) stood at $873.3 million in 2021, then dropped by 6.53% to $816.3 million in 2022, then slumped by 56.37% to $356.2 million in 2023, then fell by 6.69% to $332.3 million in 2024, then grew by 10.29% to $370.1 million in 2025.
  • Its last three reported values are $370.1 million in Q3 2025, $318.5 million for Q2 2025, and $316.6 million during Q1 2025.